Adding targeted stereotactic body radiation therapy to standard systemic treatment for people with oligometastatic urothelial (bladder) carcinoma.
Official title: Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA: ASTRA Trial
Run by Istituto Clinico Humanitas · NCT07413523 · Data updated 2026-11-12
This study will test whether adding stereotactic body radiation therapy (SBRT) to usual systemic treatment helps people with urothelial (bladder) cancer who have up to three extracranial metastases.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 44 (estimated) |
| Sponsor | Istituto Clinico Humanitas Academic / other |
| Drugs / interventions | radiation, chemotherapy, immunotherapy |
| Locations | 1 site (Rozzano, Milan) |
| Status | Recruiting |
| Started | February 16, 2026 |
| Main results expected | February 2030 |
| Study ends | February 2030 |
| Registry record updated | April 30, 2026 |
| Trial ID | NCT07413523 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age >18) with pathologically confirmed urothelial carcinoma, WHO performance status 0–2, stage IV disease with up to three extracranial metastases, adequate organ function, and planned first- or second-line systemic therapy are the ideal candidates.
✕Probably not a fit
Patients with more widespread metastatic disease (>3 extracranial lesions), poor performance status (WHO PS ≥3), prior radiation to the same target lesions, recent other cancers, or those who are pregnant/breastfeeding are unlikely to receive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized trial enrolls adults with pathologically proven urothelial carcinoma and stage IV disease with no more than three extracranial metastases who are starting first- or second-line systemic therapy. Participants are assigned to receive standard systemic therapy alone or standard therapy plus metastasis-directed stereotactic body radiotherapy (SBRT), which delivers high radiation doses in a small number of sessions. The trial tracks safety, local control of treated metastases, and clinical outcomes during follow-up to determine whether adding SBRT improves disease control compared with systemic therapy alone. The study is conducted at a single specialized cancer center in Milan, Italy.
Why it matters
Potential benefit: If successful, adding SBRT could better control metastatic sites and delay progression, potentially improving outcomes for patients with limited metastatic urothelial carcinoma.
How similar studies have gone: Stereotactic radiotherapy to oligometastases has shown benefits in other cancer types, but its role specifically in urothelial carcinoma is not yet well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * WHO performance status ≤ 2 * Pathological proven urothelial carcinoma * Stage IV disease at imaging * Maximum of 3 extracranial metastases * Indication to receive I or II line of standard systemic therapy * Adequate liver function * Adequate bone marrow function * Written informed consent Exclusion Criteria: * Inability to provide informed consent * Previous radiation therapy on the same target lesions * Pregnant or breastfeeding patients * Prior malignancy within the last five years (except adequately treated basal cell carcinoma of the skin or in situ carcinoma of the skin or in situ carcinoma of the cervix, surgically cured, or localized prostate cancer without evidence of biochemical progression) * Mental conditions rendering the patient incapable to understand the nature, scope, and consequences of the study * WHO PS \>=3
Where it's running
-
IRCCS Humanitas Research Hospital
Rozzano, Milan, Italy Recruiting
Study contacts
- Study coordinator: Marta Scorsetti, MD, Radiation oncologist
- Email: marta.scorsetti@hunimed.eu
- Phone: +39 0282248524
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Urinary Cell-Free DNA Test for Urothelial Cancer Origin
This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.
-
Specimen Collection for Validation of a New urine-based bladder cancer test
This study collects urine and tumor samples from adults being evaluated or treated for urothelial cancer to validate a next‑generation sequencing platform.
-
Comparing CT and MRI with VI-RADS for Bladder Cancer Staging
This study tests how well CT and MRI with VI-RADS can correctly stage bladder cancer before surgery in adults.
-
IDE892 alone and with IDE397 for MTAP-deleted advanced solid tumors
This trial tests IDE892 by itself and combined with IDE397 in adults whose advanced solid tumors have MTAP deletion and have progressed after standard treatments.
-
Using stereotactic body radiotherapy for patients with rare oligometastatic cancers
This study is testing if adding a special type of targeted radiation therapy to standard treatment can help people with rare cancers that have spread to a few places live longer and feel better.
-
Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy
This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.